IL‐1 receptor antagonist plus pentoxifylline and zinc for severe alcohol‐associated hepatitis
Gyöngyi Szabó(Beth Israel Deaconess Medical Center), Jennifer A. Cuthbert(University of Texas Health Science Center at Dallas), Mack C. Mitchell(Southwestern Medical Center), Svetlana Radaeva(National Institute on Alcohol Abuse and Alcoholism), Craig J. McClain(University of Louisville), Laura E. Nagy(Cleveland Clinic), Aimee Kroll‐Desrosiers(University of Massachusetts Chan Medical School), Dávid Tornai(Beth Israel Deaconess Medical Center), Arthur J. McCullough(Cleveland Clinic), Lisa Casey(The University of Texas Southwestern Medical Center), Hyesung Alice Min(University of Massachusetts Chan Medical School), Bruce Barton(University of Massachusetts Chan Medical School), M. E. Blair Holbein(The University of Texas Southwestern Medical Center), Srinivasan Dasarathy(Cleveland Clinic)
Cited by 103
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
|New England Journal of Medicine|2021|1.1k
Endpoints and clinical trial design for nonalcoholic steatohepatitis
|Hepatology|2011|757